Posted on

Biotech proved a surprisingly bright spot in 2022’s startup correction

No startup sector was entirely immune from the 2022’s market uncertainty — except maybe AI — but some proved more resilient than others. Biotech was one of the most fortunate. […]




Posted on

5 ways biotech startups can mitigate risk to grow sustainably in the long run

Omar Khalil Contributor Omar Khalil is a partner at Santé Ventures, where he focuses primarily on biotechnology and medical technology companies. The unprecedented explosion of investment in life sciences over […]




Posted on

3 tips for biotech startups seeking non-dilutive capital to survive the downturn

James Coates Contributor James Coates is the Health and Human Performance principal at Decisive Point, a venture capital and advisory firm that invests in and supports startups with emerging defense […]




Posted on

For BioNTech, the COVID-19 vaccine was simply the opening act

BioNTech’s founding story dates back to the late 1990s, when CEO and co-founder UÄŸur Åžahin, his wife and co-founder Özlem Türeci, and the rest of the seven-person founding team began […]




Posted on

In an increasingly hot biotech market, protecting IP is key

John Flavin Contributor More posts by this contributor 2021 should be a banner year for biotech startups that make smart choices early Kevin O’Connor Contributor Kevin A. O’Connor, Ph.D., is […]